Did You Know?

Editor’s Picks

Latest News

Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference

ISELIN, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch...

Additional Data from Hepion Pharmaceuticals’ Phase 2a ‘AMBITION’ Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ‘ASCEND-NASH’ Clinical Program

Pro-C3 and ALT reductions point to anti-inflammatory and antifibrotic effects of CRV431PK-PD models successfully predict early reductions in Pro-C3 and...

BioSig Increases Installation Footprint Adding St. Elizabeth’s Medical Center to Roster of Premium Medical Institutions Utilizing the PURE EP System

The Company expands into exploration of its novel signal processing technology in physiologic pacing proceduresWestport, CT, Sept. 13, 2021 (GLOBE...

error: Content is protected !!